The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis

BACKGROUND: Patients with moderate to severe rheumatoid arthritis (RA) occasionally increase their doses of tumor necrosis factor (TNF) inhibitors, especially the monoclonal antibody origin drugs such as adalimumab and infliximab, after inadequate response to the initial dose. Previous studies have...

Descripción completa

Detalles Bibliográficos
Autores principales: Incerti, Devin, Hernandez, Ervant J. Maksabedian, Tkacz, Joseph, Jansen, Jeroen P., Collier, David, Gharaibeh, Mahdi, Moore-Schiltz, Laura, Stolshek, Bradley S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391279/
https://www.ncbi.nlm.nih.gov/pubmed/32996384
http://dx.doi.org/10.18553/jmcp.2020.26.10.1236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391279/
https://www.ncbi.nlm.nih.gov/pubmed/32996384
http://dx.doi.org/10.18553/jmcp.2020.26.10.1236

Ejemplares similares